Target intelligence / Profile preview

DNA cross-link repair 1A protein (DCLRE1A)

Target
DCLRE1A
Molecular classification
Enzyme (5′–3′ exonuclease), DNA repair protein
01

Overview

DNA cross-link repair 1A protein (DCLRE1A, also known as SNM1A) is a highly conserved 5′–3′ exonuclease that plays a critical role in the repair of DNA interstrand cross-links (ICLs), structures that physically block DNA replication and transcription. DCLRE1A works with other DNA repair enzymes, particularly the XPF–ERCC1 complex, to unhook and process cross-linked DNA and is integral to maintaining genomic stability during cell division. Loss or reduction of DCLRE1A activity compromises genome integrity, sensitizes cells to DNA-damaging agents (such as cisplatin and mitomycin C), and has been implicated in rare hereditary diseases and cancer predisposition. Alternative splicing produces multiple transcript variants; DCLRE1A is a target for potential chemotherapeutic sensitization strategies and is also studied as a biomarker in DNA repair research.

Other names
SNM1ASNM1PSO2KIAA0086hSNM1AhSNM1DNA-crosslink repair gene SNM1Beta-lactamase DCLRE1ASNM1 homolog APSO2 homolog (S. cerevisiae)
02

Mechanism of action

Sensitization to DNA cross-linking chemotherapeutics by inhibiting DNA repair. Potential for increased cytotoxicity in combination with DNA-damaging agents (e.g., platinum compounds).

03

Biological functions

Repair of DNA interstrand cross-linksDNA damage responseRegulation of mitotic cell cycle checkpointMaintenance of genomic stabilityApoptosis regulation (in response to DNA damage)Cell viability
04

Disease associations

CancerFanconi anemia (complementation group B)Interstitial nephritis, karyomegalicAge-related cataractGenome instability disorders
05

Safety considerations

Inhibition of DCLRE1A may lead to increased genomic instability and non-specific toxicity in normal cells due to impaired DNA repair capacityPotential for premature aging and cell death with chronic loss of function
06

Interacting drugs

There are no FDA-approved drugs explicitly targeting DCLRE1A; however, its inhibition sensitizes cells to DNA cross-linking agents such as cisplatin and mitomycin C
07

Biomarkers

Expression levels of DCLRE1A as a potential biomarker for response to DNA-crosslinking chemotherapyDNA repair/protein activity signatures in cancer and cell viability after DNA damage

Beyond the preview

Go deeper on DNA cross-link repair 1A protein (DCLRE1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA cross-link repair 1A protein (DCLRE1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call